(Q44586681)

4 December 2017

title

Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results (English)

1 reference

4 December 2017

1 reference

J H Dalle

1

1 reference

4 December 2017

D Wall

2

1 reference

4 December 2017

Y Theoret

3

1 reference

4 December 2017

M Duval

4

1 reference

4 December 2017

L Shaw

5

1 reference

4 December 2017

D Larocque

6

1 reference

4 December 2017

C Taylor

7

1 reference

4 December 2017

J Gardiner

8

1 reference

4 December 2017

M F Vachon

9

1 reference

4 December 2017

M A Champagne

10

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 October 2003

1 reference

Bone Marrow Transplantation

4 December 2017

published in

1 reference

4 December 2017

volume

32

1 reference

4 December 2017

issue

7

1 reference

4 December 2017

page(s)

647-651

1 reference

Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and Cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

Pharmacokinetics of liposomal busulphan in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

7 January 2021

Retrospective appraisal of busulfan dose adjustment in children

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

7 January 2021

Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

7 January 2021

Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

7 January 2021

The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

7 January 2021

Quantification of busulfan in plasma by gas chromatography-mass spectrometry following derivatization with tetrafluorothiophenol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

7 January 2021

Pharmacokinetics of high-dose busulfan in children

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704209

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704209

1 reference

4 December 2017

1 reference